Loss of SPARC in bladder cancer enhances carcinogenesis and progression

Neveen Said, Henry F. Frierson, Marta Sanchez-Carbayo, Rolf A. Brekken, Dan Theodorescu

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Secreted protein acidic and rich in cysteine (SPARC) has been implicated in multiple aspects of human cancer. However, its role in bladder carcinogenesis and metastasis are unclear,with some studies suggesting it may be a promoter and others arguing the opposite. Using a chemical carcinogenesis model in Sparc-deficient mice and their wild-type littermates, we found that loss of SPARC accelerated the development of urothelial preneoplasia (atypia and dysplasia), neoplasia, and metastasis and was associated with decreased survival. SPARC reduced carcinogen-induced inflammation and accumulation of reactive oxygen species as well as urothelial cell proliferation. Loss of SPARC was associated with an inflammatory phenotype of tumor-associated macrophages and fibroblasts, with concomitant increased activation of urothelial and stromal NF-κB and AP1 in vivo and in vitro. Syngeneic spontaneous and experimental metastasis models revealed that tumorand stroma-derived SPARC reduced tumor growth and metastasis through inhibition of cancer-associated inflammation and lung colonization. In human bladder tumor tissues, the frequency and intensity of SPARC expression were inversely correlated with disease-specific survival. These results indicate that SPARC is produced by benign and malignant compartments of bladder carcinomas where it functions to suppress bladder carcinogenesis, progression, and metastasis.

Original languageEnglish (US)
Pages (from-to)751-766
Number of pages16
JournalJournal of Clinical Investigation
Volume123
Issue number2
DOIs
StatePublished - Feb 1 2013

Fingerprint

Urinary Bladder Neoplasms
Cysteine
Carcinogenesis
Neoplasm Metastasis
Proteins
Urinary Bladder
Neoplasms
Chemical Models
Survival
Carcinogens
Reactive Oxygen Species
Pneumonia
Theoretical Models
Macrophages
Cell Proliferation
Inflammation
Carcinoma
Phenotype
Growth

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Loss of SPARC in bladder cancer enhances carcinogenesis and progression. / Said, Neveen; Frierson, Henry F.; Sanchez-Carbayo, Marta; Brekken, Rolf A.; Theodorescu, Dan.

In: Journal of Clinical Investigation, Vol. 123, No. 2, 01.02.2013, p. 751-766.

Research output: Contribution to journalArticle

Said, N, Frierson, HF, Sanchez-Carbayo, M, Brekken, RA & Theodorescu, D 2013, 'Loss of SPARC in bladder cancer enhances carcinogenesis and progression', Journal of Clinical Investigation, vol. 123, no. 2, pp. 751-766. https://doi.org/10.1172/JCI64782
Said, Neveen ; Frierson, Henry F. ; Sanchez-Carbayo, Marta ; Brekken, Rolf A. ; Theodorescu, Dan. / Loss of SPARC in bladder cancer enhances carcinogenesis and progression. In: Journal of Clinical Investigation. 2013 ; Vol. 123, No. 2. pp. 751-766.
@article{455e7722cda64538a8e8399c9a35f947,
title = "Loss of SPARC in bladder cancer enhances carcinogenesis and progression",
abstract = "Secreted protein acidic and rich in cysteine (SPARC) has been implicated in multiple aspects of human cancer. However, its role in bladder carcinogenesis and metastasis are unclear,with some studies suggesting it may be a promoter and others arguing the opposite. Using a chemical carcinogenesis model in Sparc-deficient mice and their wild-type littermates, we found that loss of SPARC accelerated the development of urothelial preneoplasia (atypia and dysplasia), neoplasia, and metastasis and was associated with decreased survival. SPARC reduced carcinogen-induced inflammation and accumulation of reactive oxygen species as well as urothelial cell proliferation. Loss of SPARC was associated with an inflammatory phenotype of tumor-associated macrophages and fibroblasts, with concomitant increased activation of urothelial and stromal NF-κB and AP1 in vivo and in vitro. Syngeneic spontaneous and experimental metastasis models revealed that tumorand stroma-derived SPARC reduced tumor growth and metastasis through inhibition of cancer-associated inflammation and lung colonization. In human bladder tumor tissues, the frequency and intensity of SPARC expression were inversely correlated with disease-specific survival. These results indicate that SPARC is produced by benign and malignant compartments of bladder carcinomas where it functions to suppress bladder carcinogenesis, progression, and metastasis.",
author = "Neveen Said and Frierson, {Henry F.} and Marta Sanchez-Carbayo and Brekken, {Rolf A.} and Dan Theodorescu",
year = "2013",
month = "2",
day = "1",
doi = "10.1172/JCI64782",
language = "English (US)",
volume = "123",
pages = "751--766",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "2",

}

TY - JOUR

T1 - Loss of SPARC in bladder cancer enhances carcinogenesis and progression

AU - Said, Neveen

AU - Frierson, Henry F.

AU - Sanchez-Carbayo, Marta

AU - Brekken, Rolf A.

AU - Theodorescu, Dan

PY - 2013/2/1

Y1 - 2013/2/1

N2 - Secreted protein acidic and rich in cysteine (SPARC) has been implicated in multiple aspects of human cancer. However, its role in bladder carcinogenesis and metastasis are unclear,with some studies suggesting it may be a promoter and others arguing the opposite. Using a chemical carcinogenesis model in Sparc-deficient mice and their wild-type littermates, we found that loss of SPARC accelerated the development of urothelial preneoplasia (atypia and dysplasia), neoplasia, and metastasis and was associated with decreased survival. SPARC reduced carcinogen-induced inflammation and accumulation of reactive oxygen species as well as urothelial cell proliferation. Loss of SPARC was associated with an inflammatory phenotype of tumor-associated macrophages and fibroblasts, with concomitant increased activation of urothelial and stromal NF-κB and AP1 in vivo and in vitro. Syngeneic spontaneous and experimental metastasis models revealed that tumorand stroma-derived SPARC reduced tumor growth and metastasis through inhibition of cancer-associated inflammation and lung colonization. In human bladder tumor tissues, the frequency and intensity of SPARC expression were inversely correlated with disease-specific survival. These results indicate that SPARC is produced by benign and malignant compartments of bladder carcinomas where it functions to suppress bladder carcinogenesis, progression, and metastasis.

AB - Secreted protein acidic and rich in cysteine (SPARC) has been implicated in multiple aspects of human cancer. However, its role in bladder carcinogenesis and metastasis are unclear,with some studies suggesting it may be a promoter and others arguing the opposite. Using a chemical carcinogenesis model in Sparc-deficient mice and their wild-type littermates, we found that loss of SPARC accelerated the development of urothelial preneoplasia (atypia and dysplasia), neoplasia, and metastasis and was associated with decreased survival. SPARC reduced carcinogen-induced inflammation and accumulation of reactive oxygen species as well as urothelial cell proliferation. Loss of SPARC was associated with an inflammatory phenotype of tumor-associated macrophages and fibroblasts, with concomitant increased activation of urothelial and stromal NF-κB and AP1 in vivo and in vitro. Syngeneic spontaneous and experimental metastasis models revealed that tumorand stroma-derived SPARC reduced tumor growth and metastasis through inhibition of cancer-associated inflammation and lung colonization. In human bladder tumor tissues, the frequency and intensity of SPARC expression were inversely correlated with disease-specific survival. These results indicate that SPARC is produced by benign and malignant compartments of bladder carcinomas where it functions to suppress bladder carcinogenesis, progression, and metastasis.

UR - http://www.scopus.com/inward/record.url?scp=84873367001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873367001&partnerID=8YFLogxK

U2 - 10.1172/JCI64782

DO - 10.1172/JCI64782

M3 - Article

C2 - 23321672

AN - SCOPUS:84873367001

VL - 123

SP - 751

EP - 766

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 2

ER -